Who are bupropion immediate release (IR)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adhansia XR, dl-Methylphenidate plus Cannabidiol, Pregabalin plus BBCET, Wellbutrin, Welbutrin XL, Bupropion Hydrochloride Controlled-release.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bupropion-immediate-release-ir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

bupropion immediate release (IR) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

bupropion immediate release (IR) (bupropion-immediate-release-ir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Norepinephrine-dopamine reuptake inhibitor. Area: Neuroscience.

marketed Norepinephrine-dopamine reuptake inhibitor Dopamine transporter, Norepinephrine transporter Neuroscience Live · refreshed every 30 min

Target snapshot

bupropion immediate release (IR) (bupropion-immediate-release-ir) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bupropion immediate release (IR) TARGET	bupropion-immediate-release-ir	Pfizer	marketed	Norepinephrine-dopamine reuptake inhibitor	Dopamine transporter, Norepinephrine transporter
Adhansia XR	Adhansia XR	Purdue Pharma LP	marketed	Sympathomimetic amine combined with alpha-2A adrenergic agonist	Dopamine transporter, norepinephrine transporter, alpha-2A adrenergic receptor
dl-Methylphenidate plus Cannabidiol	dl-Methylphenidate plus Cannabidiol	University of Florida	marketed	Combination therapy: sympathomimetic amine plus phytocannabinoid	Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol)
Pregabalin plus BBCET	Pregabalin plus BBCET	University of Maryland, Baltimore	phase 3	Anticonvulsant, Analgesic, Antidepressant, Opioid partial agonist	Voltage-gated calcium channels, Opioid receptors, Dopamine transporter, Norepinephrine transporter
Wellbutrin	bupropion	GSK (GlaxoSmithKline)	marketed	NDRI (Norepinephrine-dopamine reuptake inhibitor)	Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor	1985-12-30
Welbutrin XL	Welbutrin XL	Massachusetts General Hospital	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET) and dopamine transporter (DAT)
Bupropion Hydrochloride Controlled-release	Bupropion Hydrochloride Controlled-release	University of Rochester NCORP Research Base	marketed	Norepinephrine-dopamine reuptake inhibitor (NDRI)	Norepinephrine transporter (NET) and dopamine transporter (DAT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Norepinephrine-dopamine reuptake inhibitor class)

Breath of Life International Pharma Ltd · 1 drug in this class
Hospital Universitario de Canarias · 1 drug in this class
Iowa City Veterans Affairs Medical Center · 1 drug in this class
Pablo Rodríguez del Rio · 1 drug in this class
Pfizer · 1 drug in this class
US Department of Veterans Affairs · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bupropion immediate release (IR) — Competitive Intelligence Brief. https://druglandscape.com/ci/bupropion-immediate-release-ir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab